PD-1/PD-L1抑制剂在外周T细胞淋巴瘤治疗中的研究进展#br#

外周T细胞淋巴瘤（peripheral T-cell lymphoma, PTCL）是一组高度异质性和侵袭性的非霍奇金淋巴瘤（non-Hodgkin’s lymphoma，NHL）。在目前化疗为主的治疗下，PTCL患者通常预后差，复发率高，因此需要积极探索新药来改善预后。肿瘤微环境（tumor microenvironment，TME）在多种肿瘤中发挥重要作用，程序性死亡［蛋白］-1（programmed death-1，PD-1）/程序性死亡［蛋白］配体-1（programmed death ligand-1，PD-L1）信号通路是参与肿瘤免疫逃逸的重要途径之一，针对PD-1/PD-L1通路的抑制剂在多种肿瘤中疗效显著，在PTCL的治疗上也有广阔的应用前景。研究表明在PTCL多种亚型中均有不同程度PD-1/PD-L1的表达，且PD-1单抗在部分亚型中疗效显著。现就PD-1/PD-L1在PTCL中的表达情况和其抑制剂的治疗进展作一综述。

Research progress of PD-1/PD-L1 inhibitors in the treatment of peripheral T-cell lymphomas

Peripheral T-cell lymphomas (PTCLs) are a group of highly heterogeneous and aggressive non-Hodgkin’s lymphoma (NHL). PTCL patients have poor prognosis and high rates of relapse under the current chemotherapy-based treatment. Therefore, new drugs should be developed to improve the prognosis of PTCL. Tumor microenvironment (TME) plays an important role in many tumors. Programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) signaling pathway is one of the most important pathways involved in tumor immune escape. Inhibitors of the PD-1/PD-L1 pathway have exhibited remarkable effects in the treatment of multiple tumors and have broad application prospects in PTCL. Studies have found varying degrees of expressions of PD-1 and its ligands in multiple PTCL subtypes, and the PD-1 inhibitor has significant efficacy in some subtypes. In this paper, we reviewed the expression of PD-1/PD-L1 in PTCL and the therapeutic role of its inhibitors.